ASPIRIN EFFECTS ON THE DEVELOPMENT OF CATARACTS IN PATIENTS WITH DIABETES-MELLITUS - EARLY TREATMENT DIABETIC-RETINOPATHY STUDY REPORT .16.
ASPIRIN EFFECTS ON THE DEVELOPMENT OF CATARACTS IN PATIENTS WITH DIABETES-MELLITUS - EARLY TREATMENT DIABETIC-RETINOPATHY STUDY REPORT .16.
复制标题
DOI：
10.1001/archopht.1992.01080150037023
复制
发表时间：
1992-03-01
影响因子：
--
通讯作者：
FERRIS, FL
中科院分区：
文献类型：
--
作者：
CHEW, EY;WILLIAMS, GA;FERRIS, FL
早期治疗糖尿病视网膜病变研究是一项由国家眼科研究所支持的随机临床试验，旨在评估光凝和阿司匹林对3711例轻度至重度非增殖性或早期增殖性糖尿病视网膜病变患者的影响。虽然这项研究的主要目的是评价光凝和阿司匹林对糖尿病视网膜病变的影响，但这项研究也提供了一个评价阿司匹林对白内障发展的影响的机会。没有证据表明阿司匹林的使用降低了需要摘除白内障的风险（阿司匹林或安慰剂治疗组分别为4.1%和4.3%; Mantel-Cox P = 0.77;相对风险为1.05; 99%置信区间为0.73 - 1.51）。阿司匹林的使用也没有降低发生不太广泛但视觉上显著的透镜混浊的风险（29.6% vs 28.3%; Mantel-Cox P = 0.76;相对风险0.99; 99%置信区间0.85 - 1.15）。早期治疗糖尿病视网膜病变研究结果不支持阿司匹林（剂量为650 mg/d）可降低糖尿病人群发生白内障风险的假设。
The Early Treatment Diabetic Retinopathy Study, a randomized clinical trial supported by the National Eye Institute, was designed to assess the effect of photocoagulation and aspirin in 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy. Although the primary goal of the study was to evaluate the effect of photocoagulation and aspirin on diabetic retinopathy, the study also provided an opportunity to evaluate the effects of aspirin on the development of cataract. No evidence showed that aspirin use reduced the risk of development of cataract requiring extraction (4.1% vs 4.3% in patients assigned to aspirin or placebo treatment, respectively; Mantel-Cox P = .77; relative risk, 1.05; 99% confidence interval, 0.73 to 1.51). Aspirin use also did not reduce the risk of less extensive but visually significant lens opacities developing (29.6% vs 28.3%; Mantel-Cox P = .76; relative risk, 0.99; 99% confidence interval, 0.85 to 1.15). Early Treatment Diabetic Retinopathy Study results do not support the hypothesis that aspirin (at a dose of 650 mg/d) reduces the risk of cataract development in this diabetic population.